Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Eagle Pharma, Neos Therapeutics, and Zynerba Pharma

NEW YORK, September 22, 2017 /PRNewswire/ --

If you want a Stock Review on ADMS, EGRX, NEOS, or ZYNE then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning's attention is directed to the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. In today's pre-market research, research reports have been issued by DailyStockTracker.com on Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Eagle Pharmaceuticals Inc. (NASDAQ: EGRX), Neos Therapeutics Inc. (NASDAQ: NEOS), and Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE). Register now and get full and free access to these DailyStockTracker.com research reports at:

http://dailystocktracker.com/register/

Adamas Pharmaceuticals 

On Thursday, shares in Emeryville, California headquartered Adamas Pharmaceuticals Inc. recorded a trading volume of 472,994 shares. The stock ended at $21.32, declining 0.23% from the last trading session. The Company's shares have gained 49.09% in the last one month, 26.75% over the previous three months, and 26.15% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 18.01% and 24.85%, respectively. Furthermore, shares of Adamas Pharma, which discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders, have a Relative Strength Index (RSI) of 61.11.  

On September 07^th, 2017, Adamas Pharma announced positive top-line data from the Phase-1b clinical trial of ADS-4101 (lacosamide) modified-release capsules. The study demonstrated that a 600-mg dose of ADS-4101, taken once nightly, provided a 1.7-fold increase in average lacosamide concentrations throughout the day compared to the maximum approved daily dose of 400 mg, taken as 200 mg twice daily (BID), of VIMPAT® (lacosamide) immediate-release tablets in healthy volunteers, with comparable tolerability.

On September 19^th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $26 a share to $48 a share. Access our complete research report on ADMS for free at:

http://dailystocktracker.com/registration/?symbol=ADMS

Eagle Pharmaceuticals 

Woodcliff Lake, New Jersey headquartered Eagle Pharmaceuticals Inc.'s stock finished yesterday's session 0.79% higher at $57.39 with a total trading volume of 115,140 shares. The Company's shares have gained 5.15% in the last one month. The stock is trading below its 50-day moving average by 1.67%. Furthermore, shares of Eagle Pharma, which focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the US, have an RSI of 44.62.

On September 06^th, 2017, research firm Mizuho reiterated its 'Underperform' rating on the Company's stock with a decrease of the target price from $40 a share to $37 a share. The complimentary research report on EGRX can be downloaded at:

http://dailystocktracker.com/registration/?symbol=EGRX

Neos Therapeutics 

At the close of trading on Thursday, shares in Grand Prairie, Texas headquartered Neos Therapeutics Inc. rose 2.87%, ending the day at $8.95. The stock recorded a trading volume of 940,589 shares, which was above its three months average volume of 741,930 shares. The Company's shares have surged 27.86% in the last one month, 20.95% in the previous three months, and 52.99% since the start of this year. The stock is trading 19.72% and 27.57% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Neos Therapeutics, which engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies, have an RSI of 62.36.  

On August 30^th, 2017, Neos Therapeutics announced that Vipin Garg, Ph.D., President and CEO, will present a business overview and update at the Cantor Fitzgerald Global Healthcare Conference on September 26^th, 2017, at 8:35 a.m. E.T. in New York. A live audio webcast of the event will be available under the Investor Relations page of the Company's website. Register for free on DailyStockTracker.com and get access to the latest report on NEOS at:

http://dailystocktracker.com/registration/?symbol=NEOS

Zynerba Pharmaceuticals 

Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc.'s shares ended the day 0.63% lower at $6.34 with a total trading volume of 220,805 shares. The stock has gained 6.73% in the last month. The Company's shares are trading 38.16% below their 50-day moving average. Additionally, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have an RSI of 30.63. Download your free research report on ZYNE at:

http://dailystocktracker.com/registration/?symbol=ZYNE

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com